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https://doi.org/10.1016/j.celrep.2021.109716SUMMARYFilopodia assemble unique integrin-adhesion complexes to sense the extracellular matrix. However, the
mechanisms of integrin regulation in filopodia are poorly defined. Here, we report that active integrins accu-
mulate at the tip of myosin-X (MYO10)-positive filopodia, while inactive integrins are uniformly distributed.
We identify talin and MYO10 as the principal integrin activators in filopodia. In addition, deletion of
MYO10’s FERM domain, or mutation of its b1-integrin-binding residues, reveals MYO10 as facilitating integ-
rin activation, but not transport, in filopodia. However, MYO10’s isolated FERMdomain alone cannot activate
integrins, potentially because of binding to both integrin tails. Finally, because a chimera construct generated
by swapping MYO10-FERM by talin-FERM enables integrin activation in filopodia, our data indicate that an
integrin-binding FERM domain coupled to a myosin motor is a core requirement for integrin activation in fi-
lopodia. Therefore, we propose a two-step integrin activation model in filopodia: receptor tethering by
MYO10 followed by talin-mediated integrin activation.INTRODUCTION
Filopodia are actin-rich ‘‘antenna-like’’ protrusions that are
responsible for constantly probing the cellular environment
composed of neighboring cells and the extracellular matrix
(ECM). As such, filopodia contain cell-surface receptors, such
as integrins, cadherins, and growth factor receptors, that can
interact with and interpret a wide variety of extracellular cues
(Jacquemet et al., 2015). Filopodia are especially abundant in
cells as they migrate in 3D and in vivo, where they contribute
to efficient directional migration by probing and remodeling the
surrounding ECM (Jacquemet et al., 2013, 2017; Paul et al.,
2015).
Filopodia have a unique cytoskeleton composed of tightly
packed parallel actin filaments with barbed ends oriented toward
the filopodium tip (Mattila and Lappalainen, 2008). This organiza-
tion allows molecular motors, such as unconventional myosin-X
(MYO10), to move toward and accumulate at the tips (at approx-
imately 600 nm/s) (Kerber et al., 2009). By doing so, thesemolec-
ular motors are thought to transport various proteins, including
integrins, along actin filaments to the tips of filopodia (Jacque-Cel
This is an open access article undmet et al., 2015; Arjonen et al., 2014; Berg and Cheney, 2002;
Hirano et al., 2011; Zhang et al., 2004). In particular, MYO10 is
known to bind directly to the NPxY motif of the b-integrin cyto-
plasmic tail via its FERM (protein 4.1R, ezrin, radixin, moesin)
domain (Zhang et al., 2004). At filopodia tips, integrins assemble
a specific adhesion complex that tethers filopodia to the ECM
(Alieva et al., 2019; Jacquemet et al., 2019; Gallop, 2020). Filopo-
dia adhesions contain several adhesion proteins, including talin,
kindlin, and p130Cas, but are devoid of the nascent adhesion
markers focal adhesion kinase (FAK) and paxillin (Jacquemet
et al., 2019), indicating that filopodia adhesions are distinct in
their molecular composition from other adhesion types. The sub-
sequent maturation of these filopodia adhesions into nascent
and focal adhesions can promote directional cell migration (Hu
et al., 2014; Jacquemet et al., 2016, 2019).
Integrin functions are tightly regulated by a conformational
switch that modulates ECM binding, often referred to as activa-
tion. Integrin extracellular domain conformations can range
from a bent to an extended open conformation, where the integ-
rin’s ligand affinity increases with a stepwise opening (Conway
and Jacquemet, 2019; Sun et al., 2019; Askari et al., 2009). Forl Reports 36, 109716, September 14, 2021 ª 2021 The Author(s). 1
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OPEN ACCESSb1-integrin, this unfolding can be viewed using activation-spe-
cific antibodies (Byron et al., 2009). Mechanistically, integrin ac-
tivity can be finely tuned, fromwithin the cell, bymultiple proteins
that bind to the integrin cytoplasmic tails (Conway and Jacque-
met, 2019; Sun et al., 2019; Askari et al., 2009; Bouvard et al.,
2013). For instance, talin (TLN), a key integrin activator, can
bind to the conserved membrane-proximal NPxY motif of the
b-integrin cytoplasmic tail leading to the physical separation of
the integrinɑandbcytoplasmic tails and integrin activation. Kind-
lin, another critical regulator of integrin activity, binds to mem-
brane distal conservedNxxYmotif in b-integrin cytoplasmic tails,
where it cooperates with talin to induce integrin activation (Sun
et al., 2019). Although it is clear that integrins and integrin
signaling are key regulators of filopodia function (Lagarrigue
et al., 2015; Jacquemet et al., 2016, 2019; Gallop, 2020), how in-
tegrin activity is regulated within filopodia is not fully understood.
Here, we observed that active (high-affinity) integrin accumu-
latesat filopodia tips,while inactive (unoccupied) integrin localizes
throughout filopodia.We find that integrin activation in filopodia is
locally regulated by talin and MYO10. Contrary to previous
assumptions, the FERM domain of MYO10 is not required to
transport integrins to filopodia but instead functions to activate in-
tegrins at filopodia tips. Because MYO10 contributes to integrin
activation at filopodia tips, but MYO10-FERM alone does not
directly activate integrins, our data support a two-step integrin
activationmodel in filopodia. In thismodel,MYO10 enables integ-
rin receptor tetheringat filopodia tips,which is then followedby ta-
lin-mediated integrin activation.
RESULTS
Integrin activation occurs at filopodia tips
independently of cellular forces and focal adhesions
We and others have previously described the formation of integ-
rin-mediated ECM-sensing adhesions at filopodia tips (Shibue
et al., 2012; Jacquemet et al., 2019; Lagarrigue et al., 2015;
Alieva et al., 2019; Gallop, 2020). To gain further insights into
how integrin activity is regulated in MYO10 filopodia, we first as-
sessed the spatial distribution of high-affinity and unoccupied
b1-integrin (termed active and inactive integrin, respectively,Figure 1. Active integrins accumulate at filopodia tips independently o
(A–C) U2-OS cells expressing mScarlet-MYO10 or EGFP-MYO10 were plated on
and mAb13) b1-integrin and F-actin, and imaged using structured illumination
displayed; scale bars: (main) 20 mm; (inset) 2 mm. (B) Heatmap highlighting the s
profiles. (C) The preferential recruitment of active and inactive b1-integrin to filop
intensity at filopodium tip versus shaft). Results are displayed as Tukey boxplots. (
filopodia; 12G10, n = 329 filopodia; 4B4, n = 413 filopodia; mAb13, n = 369 filop
(D and E) U2-OS cells expressing EGFP-MYO10 were plated on FN for 2 h, staine
electron microscope (SEM). (E) Representative images of single filopodia are disp
and the lower row using a backscattered electron detector (vCD). The distance o
are displayed as a density plot (n > 175 gold particles).
(F and G) U2-OS cells were plated on FN for 20 min, stained for active (F, 12G10) o
displayed; scale bars: (main) 20 mm; (inset) 1 mm.
(H–J) U2-OS cells expressing EGFP-MYO10 were plated on FN for 1 h and treated
for active b1-integrin (12G10) and imaged using SIM. (H) RepresentativeMIPs are d
filopodial localization of active b1-integrin in cells treated with DMSO, blebbistatin
are displayed as boxplots (I and J; n > 483 filopodia; three biological repeats; ***
For all panels, p values were determined using a randomization test. See also Fifor simplicity) in U2-OS cells overexpressing fluorescently
tagged MYO10 using structured illumination microscopy (SIM)
(Figures 1A–1C) and scanning electron microscopy (SEM)
(Figure 1D). We focused on b1-integrin because antibodies
recognizing the active and inactive forms of this receptor are
well characterized (Byron et al., 2009). The average distribution
of the b1-integrin species along filopodia was mapped from
the SIM and the SEM images revealing enrichment and clus-
tering of active b1-integrins at filopodia tips (Figures 1B–1E). In
contrast, inactive b1-integrins were more uniformly distributed
along the entire length of the filopodium (Figures 1A–1E). Impor-
tantly, this pattern of integrin localization was also recapitulated
in endogenous filopodia forming in actively spreading cells (in the
absence of MYO10 overexpression) (Figures 1F and 1G).
Previous work reported that forces generated by the actomy-
osin machinery are required for integrin-mediated adhesion at
filopodia tips (Alieva et al., 2019). In addition, we observed that
filopodia often align with the force generated by focal adhesions
(Stubb et al., 2020). Therefore, we investigated whether cellular
forces generated by the cell body and transmitted at focal adhe-
sions were responsible for integrin activation at filopodia tips.
U2-OS cells overexpressing fluorescently tagged MYO10 and
adhering to fibronectin were treated with DMSO, a myosin II in-
hibitor (10 mM blebbistatin), or an established focal adhesion in-
hibitor (CDK1 inhibitor, 10 mM RO-3306) (Robertson et al., 2015;
Jones et al., 2018). As expected, inhibition of myosin II or CDK1
led to rapid disassembly of focal adhesions (Figures 1H and
S1A). Blebbistatin treatment promoted longer and more
numerous filopodia, in line with our earlier report (Stubb et al.,
2020), while treatment with the CDK1 inhibitor increased filopo-
dia numbers, but not filopodia length (Figures S1B and S1C).
However, no decrease in filopodial integrin activation could be
observed when myosin II or CDK1 was inhibited (Figures 1H
and 1I). In contrast, CDK1 inhibition led to an increase in the
amount of active integrin at filopodia tips (Figures 1J and S1D).
Altogether these data indicate that integrin activation at filopodia
tips is regulated independently of cellular forces and focal adhe-
sions. Nevertheless, cellular forces are likely required to induce
filopodia adhesion maturation into focal adhesions and for effi-
cient ECM sensing (Alieva et al., 2019; Jacquemet et al., 2019).f the cellular forces generated at focal adhesion
fibronectin (FN) for 2 h, stained for active (12G10 and HUTS21) or inactive (4B4
microscopy (SIM). Representative maximum intensity projections (MIPs) are
ub-filopodial localization of the proteins stained in (A) based on their intensity
odia tips or shafts was assessed by calculating an enrichment ratio (averaged
B and C)MYO10, n = 623 filopodia; F-actin, n = 623; filopodia; HUTS21, n = 538
odia; three biological repeats).
d for active (12G10) or inactive (4B4) b1-integrin, and imaged using a scanning
layed. The upper row was acquired using a secondary electron detector (SED)
f the two b1-integrin pools from the filopodia tip was measured, and the results
r inactive (G, 4B4) b1-integrin, and imaged using SIM. Representative MIPs are
for 1 h with 10 mM blebbistatin, 10 mMRO-3306, or DMSO. Cells were stained
isplayed; scale bars: (main) 20 mm; (inset) 2 mm. (I) Heatmap displaying the sub-
, or RO-3306. (J) The average intensity of 12G10 at filopodia tips measured in (I)
p < 0.001).
gure S1.





Figure 2. Talin regulates integrin activity at filopodia tips
(A) The indicated genes were silenced in U2-OS cells expressing EGFP-MYO10 using siRNA, and the number of filopodia per cell was counted. Results are
displayed as dot plots. The effect size was calculated using PlotsOfDifferences (Goedhart, 2019). *p < 0.05.
(B–F) TLN1- and TLN2-silenced U2-OS cells transiently expressing EGFP-MYO10 were plated on FN, stained for active (12G10) or inactive (mAb13) b1-integrin,
and imaged using SIM. (B) Representative MIPs are displayed (siTLN1 #3 and siTLN2 #3); scale bars: (main) 20 mm; (inset) 2 mm. (C) Quantification of filopodia
length, from SIM images, is displayed as dot plots where the median is highlighted (n > 545 filopodia; three biological repeats). (D) Heatmap highlighting the
(legend continued on next page)






OPEN ACCESSTalin is required to activate b1-integrin at filopodia tips
The enrichment of active b1-integrin at filopodia tips (Figure 1) in-
dicates thatb1-integrin activation is likely to be spatially regulated
by one or multiple components of the filopodium-tip complex.
We and others have previously reported that several proteins
implicated in the regulation of integrin activity, including the integ-
rin activators talins and kindlins, as well as the integrin inactivator
ICAP-1 (ITGB1BP1), accumulate at filopodia tips, where their
function remains largely unknown (Lagarrigue et al., 2015; Jac-
quemet et al., 2016). In addition, we previously reported that
enhanced integrin activity often correlates with increased filopo-
dia numbers and stability (Jacquemet et al., 2016). Therefore,
we set up a microscopy-based small interfering RNA (siRNA)
screen to test the contribution of 10 known integrin activity regu-
lators on filopodia formation. Each target was silenced with two
independent siRNA oligos in U2-OS cells stably overexpressing
MYO10-GFP (Figure 2A). The effect onMYO10-positive filopodia
was scored, and the silencing efficiency of each siRNA was vali-
dated by qPCR (Figure S1E) or western blot (Figures S1F and
S1G). Of the 10 integrin regulators, only talin (combined TLN1
and TLN2) silencing significantly reduced filopodia numbers.
Because kindlin-2 (FERMT2) is a major regulator of integrin activ-
ity (Theodosiouet al., 2016) andFERMT2 localizes tofilopodia tips
(Jacquemet et al., 2019), we were surprised that FERMT2
silencing did not impact filopodia. To validate this further, we
imaged filopodia dynamics in cells silenced for both FERMT1
and FERMT2 (over 90% silencing efficiency). There was no effect
on filopodia number or dynamics, suggesting that kindlins are not
directly required to support filopodia formation or adhesion under
the conditions tested (Figures S1H and S1I).
Talin is a critical regulator of integrin activity, known to localize
to and modulate filopodia function (Lagarrigue et al., 2015; Jac-
quemet et al., 2016), and has been predicted by us and others to
trigger integrin activation at filopodia tips (Jacquemet et al.,
2019; Lagarrigue et al., 2015). To validate this notion, we plated
cells silenced for TLN1 and TLN2 on fibronectin and stained for
active b1-integrin (Figure 2B). Reduced talin expression did not
affect filopodia length (Figure 2C) but was sufficient to decrease
active b1-integrin localization at filopodia tips, as well as the per-
centage of filopodia containing active b1-integrin at their tips
(Figures 2D–2F). Altogether, our data demonstrate that talin is
required for integrin activation at filopodia tips.
The FERM domain of MYO10 is required for integrin
activation, but not localization, at filopodia tips
We previously observed that FMNL3-induced filopodia rarely
contain active b1-integrin (Jacquemet et al., 2019). A careful re-
analysis of these data, using intensity profile mapping, indicates
that active b1-integrin can be detected in only 23% of FMNL3-
induced filopodia (Figures S2A–S2D). However, this is not due
to an absence of b1-integrin because all FMNL3-induced filopo-
dia are strongly positive for inactive b1-integrins (Figures S2A–
S2D). Because integrin activation is a prominent feature ofsub-filopodial localization of the indicated proteins based on their intensity profile
average intensity of 12G10 at filopodia tips as measured in (D) is displayed as bo
detectable levels of active b1-integrin in CTRL or siTLN cells (E and F: n > 545 filop
randomization test.MYO10-positive filopodia (Figure 1), we hypothesized that
MYO10 could functionally contribute to integrin activation in filo-
podia tips.
MYO10 directly binds to integrins via its FERM domain (Hirano
et al., 2011; Zhang et al., 2004). In this context, MYO10 is thought
to transport integrins and other cargo to filopodia tips actively.
We assessed the contribution of theMYO10 FERM domain to in-
tegrin localization in filopodia by creating a MyTH4/FERM
domain deletion construct (MYO10DF) (Figure 3A). We carefully
designed this construct by considering the previously reported
MYO10-FERM domain structures (PDB: 3PZD and 3AU5) (Wei
et al., 2011; Hirano et al., 2011). MYO10DF was overexpressed
in U2-OS cells, which express low endogenous MYO10 (Young
et al., 2018; Jacquemet et al., 2016). Deleting the MYO10-
MyTH4/FERM domain led to a small but significant reduction
in filopodia number and filopodia length, in line with previous re-
ports (Zhang et al., 2004;Watanabe et al., 2010) (Figures 3B–3D).
Strikingly, the majority of MYO10DF filopodia (80%) were devoid
of active b1-integrins at their tips (Figures 3E–3H), while the uni-
form distribution of inactive b1-integrins along the filopodium
length remained unaffected (Figures 3E–3H). In line with these
results, MYO10DF-induced filopodia were much more dynamic
and seemingly unable to stabilize and attach to the underlying
ECM (Figure 3I; Video S1). Taken together, these findings
demonstrate that MYO10 and its MyTH4/FERM domain are
required for integrin activation at filopodia tips, but not for b1-in-
tegrin localization to filopodia tips (Figures 3 and S2).
Because these findings challenge the model of the MYO10
MyTH4/FERM domain acting as a cargo transporter of integrin
to filopodia tips, we tested whether the presence of inactive
b1-integrins in MYO10DF filopodia could be because of the low
endogenous MYO10 present in these cells. We expressed
wild-type (WT) or MYO10DF in MYO10-silenced U2-OS cells
(90% silencing efficiency with a 30 UTR-targeting RNA oligo)
and analyzed b1-integrin distribution using SIM (Figure S3A).
Inactive b1-integrin localization in MYO10DF filopodia was not
affected by the silencing of endogenous MYO10, further vali-
dating that the MYO10 MyTH4/FERM is not required to localize
b1-integrin to filopodia (Figures S3B–3E). Interestingly, silencing
of endogenousMYO10 led to a small decrease in the percentage
of MYO10 filopodia that contain active integrin at their tips, sug-
gesting that integrin activation at filopodia tips byMYO10may be
dose dependent (Figure S3D).
MYO10-MyTH4/FERM deletion does not influence the
localization of established filopodia tip components
Because the MYO10 MyTH4/FERM domain is thought to be the
cargo binding site in MYO10 (Wei et al., 2011), we hypothesized
that the lack of integrin activation at the tip of MYO10DF filopodia
would be caused by the absence of a key integrin activity modu-
lator. We co-overexpressed six established filopodia tip compo-
nents (Jacquemet et al., 2019), TLN1, FERMT2, CRK, DIAPH3,
BCAR1, and VASP, with either MYO10WT or MYO10DF. SIMs (n > 799 filopodia; three biological repeats, siTLN1 #3 and siTLN2 #3). (E) The
xplots (***p < 0.001). (F) Bar chart highlighting the percentage of filopodia with
odia; three biological repeats). For all panels, p values were determined using a








Figure 3. MYO10-FERM is required for integrin activation in filopodia
(A) Cartoon of the EGFP-MYO10WT and EGFP-MYO10DF constructs.
(B and C) U2-OS cells expressing EGFP-MYO10WT or EGFP-MYO10DF were plated on FN for 2 h, fixed, and imaged using a spinning-disk microscope. (B)
Representative MIPs are displayed. Scale bar: 25 mm. (C) The number of MYO10-positive filopodia per cell was then quantified (n > 85 cells, three biological
repeats; ***p < 0.001).
(D) Quantification of MYO10WT and MYO10DF filopodia length from SIM images (n > 283 filopodia; three biological repeats; ***p < 0.001).
(legend continued on next page)






OPEN ACCESSmicroscopy revealed that the localization of these proteins was
unaffected by MYO10-FERM domain deletion (Figure S4). Inter-
estingly, VASP has been previously described as an MYO10-
FERM cargo, but its localization at filopodia tips was unaffected
by MYO10-FERM deletion (Young et al., 2018; Tokuo and Ikebe,
2004; Lin et al., 2013). Altogether, our results demonstrate that
the recruitment of key filopodia tip proteins, including TLN1, is in-
dependent of the MYO10 FERM domain and suggest that
MYO10-FERMmay regulate integrin activity via another mecha-
nism than cargo transport.
The interaction betweenMYO10 and integrins regulates
integrin activation at filopodia tips
The MYO10 MyTH4/FERM domain comprises four subdomains,
namely, a MyTH4 subdomain and three FERM lobes F1, F2, and
F3. To further dissect which part of MYO10-FERM is responsible
for mediating integrin activation at filopodia tips, we generated
two additional MYO10 deletion constructs where either the
F2F3 (MYO10DF2F3) or the F3 (MYO10DF3) lobes are missing (Fig-
ureS5A).WeoverexpressedMYO10DF2F3,MYO10DF3,MYO10DF,
andMYO10WT in U2-OS cells and compared their filopodia prop-
erties (Figures S5B–S5E). MYO10DF2F3 and MYO10DF3 filopodia
were shorter than MYO10WT filopodia but longer than MYO10DF
filopodia, indicating that the MyTH4, F1, and F3 subdomains
contribute to filopodia elongation (Figure S5C). Importantly,
MYO10DF2F3 and MYO10DF3 filopodia displayed low amounts of
active b1-integrin at their tips, indicating that the MYO10 F3 sub-
domain is required to activate integrin at filopodia tips (Figures
S5D–S5F). These data also indicate that the MyTH4, F1, and F2
subdomains are not directly required tomodulate integrin activity
at filopodia tips. As others have shown that theMYO10 F3 subdo-
main contains the b1 integrin binding site (Zhang et al., 2004), our
results led us to speculate that MYO10 needs to interact with in-
tegrin directly to promote integrin activation.
Although the site where b1-integrin binds to MYO10-FERM
remains unknown, the integrin binding site has been mapped in
talin-FERM. Despite some controversy regarding the full talin-
FERM structure, superimposition of talin and MYO10 FERM do-
mains revealed that both adopt a similar fold in the b-integrin tail
binding subdomains (Figure 4A; Figure S6A) (Zhang et al., 2020;
Elliott et al., 2010). Therefore, we can predict mutations likely to
disturb the MYO10-integrin interaction (S2001_F2002insA and
T2009D; Figure 4B). The introduction of these mutations in
MYO10-FERM (FERMITGBD) led to a 64% reduction in the ability
of b1-integrin tail peptides to pull down GFP-tagged MYO10-
FERM domains from cell lysate, indicating that these mutations
can impede the interaction between MYO10 and integrins (Fig-
ure 4C). Cells expressing full-length MYO10 with the integrin-(E) U2-OS cells expressing EGFP-MYO10DF were plated on FN for 2 h, staine
Representative MIPs are displayed; scale bars: (main) 20 mm; (inset) 2 mm.
(F) Heatmap highlighting the sub-filopodial localization of the proteins stained in
repeats).
(G) The average intensity of 12G10 at filopodia tips and of mAb13 in filopodia m
(H) Bar chart highlighting the percentage of MYO10WT and MYO10DF-induced filo
(H and G; n > 250 filopodia; three biological repeats).
(I) U2-OS cells expressing EGP-MYO10WT or EGFP-MYO10DF were plated on FN a
S1). MYO10 spot lifetime is displayed as boxplots (three biological repeats; n >
For all panels, p values were determined using a randomization test. See also Fibinding mutation (MYO10ITGBD) generated filopodia to the same
extent as cells expressingMYO10WT (Figures4Dand4E), butMY-
O10ITGBD filopodia were shorter than MYO10WT filopodia (Fig-
ure 4F). Notably, only 25% of MYO10ITGBD filopodia contained
detectable levels of active b1-integrin at their tips (Figures 4G–
4I). Thus, we conclude that an intact integrin binding site within
MYO10-FERM is required for MYO10 to activate b1-integrin at fi-
lopodia tips efficiently.
Unlike Talin-FERM, the MYO10 MyTH4/FERM domain is
not able to activate integrins
The talin-FERM domain is necessary and sufficient to activate
integrins (Anthis et al., 2009; Lilja et al., 2017). Given our data
indicating that MYO10-FERM is required to activate integrin at fi-
lopodia tips (Figures 3 and 4), we tested whether MYO10-FERM
could modulate integrin activity similarly to talin-FERM. We em-
ployed a flow cytometric assay tomeasure active cell-surface in-
tegrins relative to total cell-surface integrins (Lilja et al., 2017)
(Figures 5A–5C). As expected, overexpression of the talin-
FERMdomain significantly increased integrin activity (Figure 5A).
In contrast, overexpression of the MYO10-FERM domain failed
to activate integrins and instead led to a small but highly repro-
ducible decrease in integrin activity in CHO and U2-OS cells
(Figures 5A and 5B). Similar data were obtained in U2-OS cells
overexpressing full-length MYO10 (Figure 5B). Conversely,
silencing of MYO10 increased integrin activity in MDA-MB-231
cells, where mutant p53 drives high endogenous MYO10 levels
(Arjonen et al., 2014), and this was reversed by the reintroduction
of full-length MYO10 (Figure 5C and S6B). Consistent with
decreased integrin activation, MYO10-FERM expression attenu-
ated cell adhesion/spreading on fibronectin over time (Figures
5D–5F) (Hamidi et al., 2017). Altogether, our data indicate that,
even though theMYO10-FERM domain is necessary for spatially
restricted integrin activation at filopodia tips, the MYO10-FERM
domain alone cannot activate integrins.
Unlike Talin-FERM, MYO10-FERM binds to both a- and
b-integrin tails
Despite being homologous domains with high structural similar-
ity, the functional difference between MYO10-FERM and Talin-
FERM domains prompted us to compare their binding affinities
to integrin cytoplasmic tails. Recombinant MYO10- and talin-
FERM were expressed in bacteria, purified (Figure S6C), and
their binding affinity to integrin a and b tails was measured using
microscale thermophoresis (Figures 6A and 6B; see STAR
Methods for details) (Jerabek-Willemsen et al., 2014). As ex-
pected, talin-FERM interacted with the b1-integrin tail (measured
affinity of 4.7 mM), but not with a-integrin tails (Goult et al., 2009).d for active (12G10) or inactive (mAb13) b1-integrin, and imaged using SIM.
(E) generated from their intensity profiles (n > 250 filopodia; three biological
easured in (F) are displayed as boxplots (***p < 0.001).
podia with detectable levels of active (12G10) and inactive (mAb13) b1-integrin
nd imaged live using an Airyscan confocalmicroscope (scale bar: 25 mm; Video
33 cells; ***p < 0.006).
gures S2–S4.







Figure 4. An intact integrin binding site
within MYO10-FERM is required for
MYO10-mediated integrin activation at fi-
lopodia tips
(A) Visualization of MYO10-FERM (PDB: 3PZD)
(Wei et al., 2011) and TLN1-FERM (PDB: 6VGU)
(Zhang et al., 2020) structures. The integrin-
binding region on the talin-FERM domain is
highlighted and magnified.
(B) The structure of the MYO10-FERM mutated
on the predicted integrin binding site was
modeled using SWISS-MODEL (Waterhouse
et al., 2018) based on the MYO10-FERM struc-
ture (PDB: 3PZD).
(C) b1-Integrin tail peptide pull-down in U2-OS
cells expressing EGFP-tagged MYO10-FERM
wild-type (WT; FERMWT) or mutant (FERMITGBD)
or EGFP alone. MYO10-FERM recruitment to the
b1-integrin tail was assessed using western blot
(n = 3, ***p = 0.008, Welch’s t test). Individual
repeats are color-coded (Lord et al., 2020;
Goedhart, 2021).
(D) U2-OS cells transiently expressing full-length
EGFP-MYO10WT or EGFP-MYO10ITGBD were
plated on FN for 2 h, fixed, and imaged using a
spinning-disk microscope. The number of
MYO10-positive filopodia per cell was quantified
(n > 81 cells; three biological repeats).
(E–H) U2-OS cells expressing EGFP-MYO10WT
or EGFP-MYO10ITGBD were plated on FN for 2 h,
stained for active b1-integrin (12G10), and
imaged using SIM. (E) Representative MIPs are
displayed; scale bars: (main) 20 mm; (inset) 2 mm.
(F) Quantification of MYO10WT and MYO10ITGBD
filopodia length from SIM images (n > 693 filo-
podia; three biological repeats; ***p < 0.001). (G)
Heatmap highlighting the sub-filopodial localiza-
tion of the indicated proteins based on their in-
tensity profiles. (H) The average intensities of
12G10 at filopodia tips measured in (G) are dis-
played as boxplots (***p < 0.001).
(I) Bar chart highlighting the percentage of MY-
O10WT and MYO10ITGBD filopodia with detect-
able levels of active b1-integrin (G–I; n > 693
filopodia; three biological repeats).
For all panels except (C), p values were deter-
mined using a randomization test. NS, no statis-
tical difference between the mean values of the




OPEN ACCESSThis result agrees with measurements done by others using the
same method (Haage et al., 2018). Interestingly, MYO10-FERM
bound to the b1-integrin tail with a slightly lower affinity than ta-
lin-FERM (measured affinity of 25.1 mM) (Figures 6A and 6B). This
result indicates that talin may be able to outcompete MYO10 for
integrin binding.
Unexpectedly, our results indicated that, in contrast with talin-
FERM, a-integrin tails also interact with MYO10-FERM in vitro
(Figures 6A and 6B) and with endogenous MYO10 in cell lysate
(Figure 6C). The ability of MYO10 to interact with both a- and
b-tail peptides appeared to be specific because the clathrin8 Cell Reports 36, 109716, September 14, 2021adaptor AP2m, a known a2-integrin tail-specific binder (De Fran-
ceschi et al., 2016), was pulled down only with the a2-integrin tail
(Figure 6C). The MYO10-a-tail interaction was dependent on the
highly conserved membrane-proximal GFFKR motif, present in
most integrin a tails (De Franceschi et al., 2016). Mutation of the
motif in the a2-integrin tail (FF/AA mutation, named ITGA2GAAKR)
abolished the binding of recombinant MYO10-FERM in vitro (Fig-
ure 6D) and in pull-downs with full-length MYO10 (Figure 6E).
Importantly, AP2m recruitment was unaffected by the mutation
(AP2m binds to a separate motif in the a2-tail) (Figure 6E).




Figure 5. The MYO10 FERM domain inhibits integrin activity
(A) CHO cells expressing EGFP, EGFP-TLN1FERM, or EGFP-MYO10FERMwere either incubated with an Alexa 647-labeled FN fragment (FN7–10) and fixed or fixed
directly and stained for ITGA5 (PB1). Samples were then analyzed by flow cytometry, and the integrin activity index was calculated (see STAR Methods; *p =
0.012, **p = 0.0062, one-sample t test; n = 7 of biological repeats).
(B and C) Cells transiently expressing various EGFP constructs (U2-OS) (B) or silenced for MYO10 (siMYO10 #7) and expressing EGFP or EGFP-MYO10 (MDA-
MB-231) (C) were fixed and stained for active (9EG7) or total b1-integrin (P5D2). Staining intensity was recorded by flow cytometry, and integrin activation was
calculated as a 9EG7/P5D2 ratio (*p < 0.05, Student’s two-tailed t test; B, n = 5 biological repeats; C, n = 4 biological repeats).
(D and E) CHO or U2-OS cells transiently expressing EGFP or EGFP-MYO10FERMwere left to adhere to FN, and their spreading wasmonitored over time using the
xCELLigence system. The cell index over time is displayed; gray areas indicate the 95% confidence intervals. The cell index at 60 min is also displayed as a bar
chart (***p < 0.001, Student’s two-tailed t test; D, n = 4 biological repeats; E, n = 3 biological repeats).
(F) U2-OS cells transiently expressing EGFP or EGFP-MYO10FERM were seeded on FN and allowed to spread for 40 min prior to fixation. Samples were imaged
using a confocal microscope and the cell area measured (***p < 0.001, randomization test; n > 188 cells; 3 biological repeats; scale bars: 16 mm).
For all panels, error bars represent the standard error of the mean. See also Figure S6.










Figure 6. MYO10 binds to both a- and b-integrin tails
(A and B) Recombinant TLN1FERM and MYO10FERM domain and a 6xHis CTRL peptide were labeled, and their binding to integrin tails was recorded using
microscale thermophoresis. Graphs and KD values were generated by pooling together three independent experiments.
(C) Integrin tail pull-downs were performed from U2-OS cell lysates using magnetic beads. The recruitment of MYO10 and AP2m was then analyzed by western
blot (n = 3 biological experiments).
(D) Recombinant MYO10FERM was labeled, and its binding to the intracellular tails of WT ITGA2 (ITGA2WT) or ITGA2 mutated on the GFFKR consensus site
(ITGA2GAAKR) was recorded using microscale thermophoresis (three independent experiments).
(E) Integrin tail pull-downs were performed from cell lysate generated from U2-OS cells stably expressing EGFP-MYO10FERM. The recruitment of endogenous
MYO10, EGFP-MYO10FERM, and AP2m was then analyzed by western blot (n = 3 biological experiments).
(F) CHO cells transiently expressingmScarlet-MYO10 and full-lengthGFP-ITGA2WT or GFP-ITGA2GAAKRwere plated on collagen I for 2 h, fixed, and imaged using
a spinning-disk microscope. Representative MIPs are displayed. Scale bar: 25 mm. The number of MYO10-positive filopodia per cell was then quantified (n > 107
cells, four biological repeats; ***p < 0.001, randomization test).
(G) Different EGFP-tagged MYO10 FERM domains or EGFP alone were pulled down from U2-OS lysate using a2-integrin tail peptide. MYO10 FERM recruitment
to a2-integrin tail was assessed using western blot (n = 3 biological experiments).











Figure 7. MYO10-FERM fine-tunes integrin activity at filopodia tips
(A) Cartoon of the EGFP-MYO10WT and EGFP-MYO10TF constructs.
(B–E) U2-OS cells expressing EGFP-MYO10WT or EGFP-MYO10TF were plated on FN for 2 h, fixed, and imaged using a spinning disk or an Airyscanmicroscope.
(B) Representative MIPs acquired on a spinning-disk confocal are displayed; scale bar: 25 mm. (C) An image acquired on an Airyscan microscope is displayed;
scale bars: (main) 25 mm; (inset) 5 mm. (D) The number of MYO10-positive filopodia per cell was quantified (n > 74 cells; three biological repeats). (E) Quantification
of MYO10WT and MYO10TF filopodia length from SIM images (n > 512 filopodia; three biological repeats; ***p < 0.001).
(F) U2-OS cells expressing EGFP-MYO10WT or EGFP-MYO10TF were plated on FN and imaged live using an Airyscan microscope. The MYO10 spot lifetime was
plotted and displayed as boxplots (three biological repeats, n > 33 cells).
(legend continued on next page)






OPEN ACCESSintegrin b tails, in line with previous reports (Zhang et al., 2004;
Hirano et al., 2011), revealing a previously unknown interaction
between MYO10-FERM and the GFFKR motif in integrin a tails.
Binding to both integrin tails has been demonstrated as a mech-
anism for Filamin-A-mediated integrin inactivation (Liu et al.,
2015) and, thus, may be the underlying reason for the inability
of MYO10-FERM alone to activate integrins.
To test the relevance of the GFFKR a-integrin tail motif in filopo-
dia induction, we overexpressed full-length WT ITGA2 and
ITGA2GAAKR in CHO cells (these cells lack endogenous collagen-
binding integrins) and investigated MYO10 filopodia formation
oncollagen I (Figure6F). ITGA2GAAKR localizes to theplasmamem-
brane and is expressed at similar levels toWT inCHOcells (Alanko
et al., 2015). ITGA2GAAKR-expressing cells generated fewer filopo-
dia than cells expressing WT ITGA2, indicating that the GFFKR
motif in the ITGA2 tail contributes to filopodia formation.We could
not directly assess the relevance of theMYO10-a-integrin interac-
tion to filopodia functionsbecause theMYO10ITGBD construct also
displayed reduced binding toward ITGA2 (Figure 6G).
MYO10-FERM domain fine-tunes integrin activity at
filopodia tips
To further investigate how MYO10-FERM regulates integrin ac-
tivity in filopodia and the functional differences between talin
and MYO10 FERM domains, we created a chimera construct,
where the FERM domain from MYO10 was replaced by the
one from TLN1 (MYO10TF) (Figure 7A). Both MYO10WT and MY-
O10TF strongly accumulated at filopodia tips (Figures 7B and
7C). Interestingly, in a small proportion of cells (below 1%), MY-
O10TF also localized to enlarged structures connected to stress
fibers that are reminiscent of focal adhesions (Figure 7C).
Cells overexpressing MYO10TF generated filopodia to the
same extent as cells expressingMYO10WT (Figure 7D).MYO10TF
filopodia were slightly shorter than MYO10WT filopodia but of
comparable dynamics (Figures 7E and 7F). These results show
that the talin-FERM can replace the MYO10-FERM domain,
and highlight an unanticipated level of interchangeability be-
tween integrin-binding FERM domains in regulating filopodia
properties. Importantly, active b1-integrin accumulated more
efficiently at the tips of MYO10TF filopodia, and MYO10TF filopo-
dia weremore likely to contain active b1-integrin at their tips than
MYO10WT filopodia (Figures 7G–7J). Silencing of TLN1 and TLN2
still impeded MYO10TF filopodia formation, indicating that talin-
FERM fused to the MYO10 motor is insufficient to substitute for
the lack of endogenous full-length talin (Figures S6C and S6D).
The increased amount of active b1-integrin at the tip of MYO10TF
filopodia is likely due to the ability of talin-FERM to activate integ-
rin directly (Figure 5) or because talin-FERM binds to integrins
with a higher affinity than MYO10-FERM (Figure 6). Altogether,(G) U2-OS cells expressing EGFP-MYO10TF were plated on FN for 2 h, staine
Representative MIPs are displayed; scale bars: (main) 20 mm; (inset) 2 mm.
(H) Heatmap highlighting the sub-filopodial localization of active b1-integrin in c
biological repeats).
(I) The average intensity of active b1-integrin (12G10) at filopodia tips and of inac
(J) Bar chart highlighting the percentage of MYO10WT and MYO10TF filopodia wit
three biological repeats).
For all panels, p values were determined using a randomization test.
12 Cell Reports 36, 109716, September 14, 2021our data indicate that an integrin-binding proficient FERM
domain coupled to a myosin motor is required to activate, but
not to transport, integrin in filopodia (Figures 2 and 5).
DISCUSSION
Here, we observed that active integrin accumulates at filopodia
tips, while inactive integrin localizes throughout filopodia shafts.
We find that integrin activation in filopodia is uncoupled from
focal adhesions or the actomyosin machinery but is instead
regulated by talin and MYO10. Contrary to previous assump-
tions, MYO10 is not required to localize integrin to filopodia,
but its integrin-binding FERMdomain is required for integrin acti-
vation at filopodia tips. We find, however, that, unlike talin-
FERM,MYO10-FERM itself does not promote integrin activation.
MYO10 and integrins also localize and modulate other cellular
structures, including retraction fibers, invadopodia, growth
cone filopodia, and neuronal spines (Schoumacher et al., 2010;
Lin et al., 2013; Lilja and Ivaska, 2018; Peláez et al., 2019).
Here, we focused on the role of MYO10 in modulating integrin
in filopodia. Still, it is tempting to speculate that MYO10
may also regulate integrin activity in these other actin-rich
protrusions.
We find that MYO10-FERM interaction with integrins is
required to localize active integrin to filopodia tips. The simplest
assumption would be that MYO10, in its typical capacity as a
myosin motor, specifically transports active integrin to filopodia
tips. However, our data suggest otherwise as (1) the MYO10
FERM domain alone inactivates integrins, and therefore integ-
rins would not be in an active state during transport; (2) talin
is required to localize active integrins at filopodia tips; and (3)
integrin activation is thought to be a fast and tightly regulated
process (Sun et al., 2019), with all evidence pointing to an
on-site integrin activation mechanism in filopodia tips. In addi-
tion, direct transport of integrin by MYO10 to filopodia tips has
yet to be formally observed. Our data do not exclude the pos-
sibility that MYO10 can directly transport integrin in filopodia.
Testing this would require performing two-color, single-mole-
cule imaging of MYO10 and integrin to see if they move toward
filopodia tips together. However, we find integrins abundantly in
filopodia regardless of the MYO10 status. Altogether, we pro-
pose that inactive integrins localize along the filopodia plasma
membrane via membrane diffusion and are activated at filopo-
dia tips in a two-step process by MYO10 and talin. In this
model, MYO10 could tether integrins at filopodia tips because
of its motor domain and provide resistance against the actin
retrograde flow present in filopodia (Bornschlögl et al., 2013;
Lidke et al., 2005) allowing sufficient time for talin-mediated
activation.d for active (12G10) or inactive (mAb13) b1-integrin, and imaged using SIM.
ells expressing EGFP-MYO10WT or EGFP-MYO10TF (n > 512 filopodia; three
tive b1-integrin (mAb13) in filopodia are displayed as boxplots (***p < 0.001).
h detectable levels of active and inactive b1-integrin (I and J, n > 255 filopodia;
Article
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OPEN ACCESSThe precise mechanisms favoring integrin binding to MYO10
or talin in filopodia remain to be elucidated. One possibility is
that talin-FERM outcompetes MYO10-FERM. Indeed, our
in vitro experiments indicate that talin-FERM has, in solution, a
higher affinity for integrin b tail compared with MYO10-FERM.
In addition, talin affinity for b-integrin tails will be even stronger
in cells because of the presence of negatively charged mem-
brane phosphoinositides that interact with talin-FERM (Chintha-
lapudi et al., 2018; De Franceschi et al., 2018), and which are
known to accumulate at filopodia tips (Jacquemet et al., 2019).
Interestingly, althoughMYO10 and talin FERMdomains structur-
ally adopt a very similar fold, we find that these two FERM do-
mains are functionally distinct. MYO10-FERM is not capable of
directly activating integrin and can interact with both integrin
tails. Yet, remarkably, swapping MYO10-FERM with talin-
FERM fully supported filopodia function and integrin activation
at filopodia tips, suggesting unanticipated interchangeability be-
tween these FERM domains in spatially regulating integrin acti-
vation in filopodia. Other FERM domain-containing myosins,
including MYO7 and MYO15, also localize to filopodia tips (Jac-
quemet et al., 2019; Arthur et al., 2019), where their roles are
mostly unknown; future work will examine the contribution of
these unconventional myosins to filopodia functions.STAR+METHODS
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Theodosiou, M., Widmaier, M., Böttcher, R.T., Rognoni, E., Veelders, M.,
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Antibodies
Mouse anti-human active b1 integrin
(12G10)
In house RRID:AB_775726
Mouse anti-human b1 integrin (HUTS21) BD Biosciences catalog number: 556048;
RRID:AB_396319
Rat anti-human b1 integrin (9EG7) BD Biosciences catalog number: 553715;
RRID:AB_395001
Mouse anti-human b1 integrin (4B4) Beckman Coulter catalog number: 6603113;
RRID:AB_10638675
Rat anti-human b1 integrin (mAb13) In house RRID:AB_394479












Novus Biologicals catalog number: NBP2-50320;
RRID:AB_11159092
Mouse monoclonal anti-human TLN2
(68E7)
Novus Biologicals catalog number: NBP2-50322
Mouse monoclonal anti-b-actin (AC-15) Merck catalog number: A1978;
RRID:AB_476692
Mouse monoclonal anti-PAX (349) BD Biosciences catalog number: 610051;
RRID:AB_397463
Rabbit monoclonal anti-AP2m Novus Biological catalog number: EP2695Y;
RRID:AB_2258308
Rabbit polyclonal anti-GFP Abcam catalog number: Ab290;
RRID:AB_303395
Rabbit polyclonal anti-MYO10 Novus Biologicals catalog number: 22430002;
RRID:AB_2148055
Rabbit polyclonal anti-kindlin-1
(recognizes kindlin 1 and 2)
Abcam catalog number: ab68041;
RRID:AB_1603823
Chemicals, peptides, and recombinant proteins
RO-3306 Merck catalog number: SML0569
Blebbistatin Stemcell technologies catalog number: 72402
Bovine plasma fibronectin Merck catalog number: 341631
Collagen I Merck catalog number: C8919-20ML








conserved region of the a2-integrin tail
(WKLGFFKRKYEKM) custom peptide
LifeTein N/A
a2-integrin tail peptide where the GFFKR
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Experimental models: Cell lines
U2-OS osteosarcoma cells Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell
Cultures, Braunschweig DE
catalog number: ACC 785
MDA-MB-231 triple-negative human
breast adenocarcinoma
ATCC catalog number: HTB-26
CHO-K1 cells ATCC catalog number: CCL-61
Oligonucleotides
siACTN1 #5 QIAGEN catalog number: Hs_ACTN1_5, SI00299131
siACTN1 #2 QIAGEN catalog number: Hs_ACTN1_2, SI00021917
siTNS3 #1 QIAGEN catalog number: Hs_TENS1_1, SI00134372
siTNS3 #2 QIAGEN catalog number: Hs_TNS3_2, SI02778643
siTNS1 #3 QIAGEN catalog number: Hs_TNS_3, SI00134106
siTNS1 #4 QIAGEN catalog number: Hs_TNS_4, SI00134113
siFERMT1 #5 QIAGEN catalog number: Hs_C20orf42_5,
SI04269181
siFERMT1 #7 QIAGEN catalog number: Hs_C20orf42_7,
SI04307219
siFERMT1 #8 QIAGEN catalog number: Hs_C20orf42_8,
SI04352978
siFERMT2 #1 QIAGEN catalog number: Hs_FERMT2_1,
SI04952542
siFERMT2 #3 QIAGEN catalog number: Hs_FERMT2_3,
SI04952556
siCIB1 #5 QIAGEN catalog number: Hs_CIB1_5, SI02657102
siCIB #7 QIAGEN catalog number: Hs_CIB1_7, SI03164476
siSHARPIN #2 QIAGEN catalog number: Hs_SHARPIN_2,
SI00140182
siSHARPIN #5 QIAGEN catalog number: Hs_SHARPIN_5,
SI03067344
siITGB1BP1 #5 QIAGEN catalog number: Hs_ITGB1BP1_5,
SI03129385
siITGB1BP1 #8 QIAGEN catalog number: Hs_ITGB1BP1_8,
SI04332832
siTLN1 #2 QIAGEN catalog number: Hs_TLN1_2, SI00086968
siTLN1 #3 QIAGEN catalog number: Hs_TLN1_3, SI00086975
siTLN2 #3 QIAGEN catalog number: Hs_TLN2_3, SI00109277
siTLN2 #4 Dharmacon catalog number: LQ’012909-00-0002
siMYO10 #5 QIAGEN catalog number: Hs_MYO10_5,
SI04158245
siMYO10 #6 QIAGEN catalog number: Hs_MYO10_6,
SI04252822
siMYO10 #7 QIAGEN catalog number: Hs_MYO10_7,
SI05085507
Primers for TNS1 (cca gac acc cac ctg act
tag; ttg gtg cat tct cag tgg tg; probe 58)
IDT N/A
Primers for ACTN1 (gcc tca tca gct tgg gtt
at; cat gat gcg ggc aaa ttc; probe 7)
IDT N/A
Primers for FERMT1 (aga cgt cac act gag
agt atc tgg; tct gac cag tct tgg gat ata ttg;
probe 25)
IDT N/A
(Continued on next page)
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Primers for TNS3 (agg ctg cct gac aca gga;
agg ggc tgt tca gca gag; probe 57)
IDT N/A
Primers for TLN1 (ccc tta cct ggg gag aca
at; gag ctc acg gct ttg gtg; probe 61)
IDT N/A
Primers for CIB1 (agt tcc agc acg tca tct cc;
gct gct gtc aca gga caa tc; probe 17)
IDT N/A
Primers for ITGB1BP (ttg aag ggc cat tag
acc tg; gaa caa aag gca act ttc cat
c; probe 61)
IDT N/A
Primers for FERMT2 (taa aa cat ggc gtt tca
gca; cat ctg caa act cta cgg tgac; probe 48)
IDT N/A
Primers for SHARPIN (ccc tgg ctg tga gat
gtg ta; ggc cac tct ccc ctt gta ac; probe 83)
IDT N/A
Primers for FLNA (gtc acc ggt cgc tct cag;
agg gga cgg ccc ttt aat; probe 32)
IDT N/A
Primers for TLN2 (ggt cat ggt tgg gca gat;
gca tgc ttg tgt tga tgg tc; probe 40)
IDT N/A
Recombinant DNA
EGFP-MYO10FERM This study, Addgene catalog number: 145140
His-tagged MYO10FERM This study N/A
EGFP-MYO10-FERMITGBD This study N/A
EGFP-MYO10DF This study, Addgene catalog number: 145816
mScarlet-I-MYO10DF This study, Addgene catalog number: 145139
EGFP-MYO10TF This study, Addgene catalog number: 145141
EGFP-MYO10ITGBD This study N/A
EGFP-MYO10DF2F3 This study N/A
EGFP-MYO10DF3 This study N/A
EGFP-MYO10 Addgene (Emanuel Strehler)
(Bennett et al., 2007)
catalog number: 47608
CRK-GFP Addgene (Ken Yamada) catalog number: 50730
VASP-GFP Addgene (Michael Davidson) catalog number: 54297
DIAPH3-GFP Addgene (Michael Davidson) catalog number: 54158
BCAR1-GFP Daniel Rösel (Charles University in Prague,
Czech Republic) (Branis et al., 2017).
N/A
FERMT2-GFP Maddy Parsons (King’s College
London, UK)
N/A
GFP-ITGA2 (Pellinen et al., 2006) N/A
GFP-ITGA2GAAKR (Pellinen et al., 2006) N/A
mScarlet-MYO10 (Jacquemet et al., 2019) N/A
GFP-TLN1 (Kopp et al., 2010) N/A
GFP-TLN1FERM (Goult et al., 2010) N/A
His-TLN1FERM (Goult et al., 2010) N/A
Software and algorithms
FiloMAP (Jacquemet et al., 2019) https://github.com/guijacquemet/FiloMAP
RStudio (1.3.1093) Foundation for Open Access Statistics. https://www.rstudio.com/
Fiji (2.1) (Schindelin et al., 2012) https://fiji.sc/
TrackMate (Tinevez et al., 2017) https://imagej.net/plugins/trackmate/
PlotsOfDifferences (Goedhart, 2019) https://huygens.science.uva.nl/
PlotsOfDifferences/
(Continued on next page)
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PlotsOfData (Postma and Goedhart, 2019) https://huygens.science.uva.nl/
PlotsOfData/
SuperPlotsofData (Goedhart, 2021) https://huygens.science.uva.nl/
SuperPlotsOfData/
MO.Affinity software NanoTemper https://nanotempertech.com/
monolith-mo-control-software/
SlideBook 6 Intelligent Imaging Innovations, Inc https://www.intelligent-imaging.com/
slidebook
SoftWorx GE Healthcare N/A
Zen Black (2.3) Zeiss https://www.zeiss.com/microscopy/int/
products/microscope-software/zen.html
Other





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Guillaume
Jacquemet (guillaume.jacquemet@abo.fi).
Materials availability
Several of the plasmids generated in this study have been deposited to Addgene: EGFP-MYO10FERM (catalog number: 145140),
EGFP-MYO10DF (catalog number: 145816), mScarlet-I-MYO10DF (catalog number: 145139), EGFP-MYO10TF (catalog number:
145141). The other plasmids generated in this study will also be available on Addgene soon.
Data and code availability
The authors declare that the data supporting the findings of this study are available within the article and from the authors upon
request. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon
request. The ImageJ macro as well as the R code used to generate the filopodia maps were previously described and are available
on GitHub (https://github.com/guijacquemet/FiloMAP).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
U2-OS (human osteosarcoma) and MDA-MB-231 (triple-negative human breast adenocarcinoma) cells were grown in DMEM
(Dulbecco’s Modified Eagle’s Medium with HEPES modification; Sigma, D1152) supplemented with 10% fetal bovine serum
(FCS) (Biowest, S1860). CHO cells were cultured in alpha-MEM, supplemented with 5% FCS and L-glutamine.
METHOD DETAILS
Plasmids and transfection
U2-OS, MDA-MB-231, and CHO cells were transfected using Lipofectamine 3000 and the P3000TM Enhancer Reagent (Thermo
Fisher Scientific) according to the manufacturer’s instructions. The U2-OS MYO10-GFP lines were generated by transfecting U2-
OS cells using Lipofectamine 3000 (ThermoFisher Scientific), selected using Geneticin (ThermoFisher Scientific; 400 mg.ml-1 final
concentration) and sorted for green fluorescence using a fluorescence-assisted cell sorter (FACS). All cell lines tested negative
for mycoplasma.
Plasmids
The construct encoding the EGFP-tagged MYO10-FERM domain (EGFP-MYO10FERM) was designed using the boundaries from the
MYO10-FERM crystal structure (Wei et al., 2011). The MYO10 coding region 1480-2053 was amplified by PCR (primers: 50-ATT AGA
GAA TTC AAC CCG GTG GTC CAG TGC-30, 50-ATT AGA GGT ACC TCA CCT GGA GCT GCC CTG-30), and the resulting PCR prod-
ucts were ligated into pEGFP-C1 using the EcoRI and KpnI restriction sites. To generate the EGFP-MYO10-FERMITGBD mutant, a
synthetic DNA sequence (gene block, IDT) encoding the MYO10 FERM domain (as indicated above) containing the appropriate mu-
tations (S2001_F2002insA/T2009D) was inserted into pEGFP-C1 using the EcoRI/KpnI restriction sites. To generate the His-tagged
MYO10FERM plasmid, the MYO10-FERM domain (boundaries 1504-2058 in MYO10) was amplified by PCR (primers: 50-ATT AGACell Reports 36, 109716, September 14, 2021 e4
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the NotI and EcoRI restriction sites.
TheMYO10MyTH/FERMdeletion construct (EGFP-MYO10DF) was generated by introducing a premature stop codon in full-length
EGFP-MYO10 (boundaries 1-1512 in MYO10) using a gene block (IDT). The gene block was inserted in EGFP-MYO10 using the PvuI
and XbaI restriction sites.
The mScarlet-I-MYO10DF construct was created from EGFP-MYO10DF by swapping the fluorescent tag. The mScarlet-I (Bindels
et al., 2017) coding sequence, acquired as a gene block (IDT), was inserted in EGFP-MYO10DF using the NheI and KpnI restriction
sites.
TheMYO10/TLN1 chimera construct (EGFP-MYO10TF) was generated by swapping the MYO10-FERM domain (boundaries 1504-
2056 in MYO10) with the TLN1-FERM domain (boundaries 1-398 in TLN1) using a gene block (IDT). The gene block was inserted in
EGFP-MYO10 using the PvuI and XbaI restriction sites.
The EGFP-MYO10ITGBD construct was generated by replacing the wild-type MYO10-FERM domain (boundaries 1504-2056 in
MYO10) with a MYO10 FERM domain containing the required mutations (S2001_F2002insA/T2009D) using a gene block (IDT).
The gene block was inserted in EGFP-MYO10 using the PvuI and XbaI restriction sites.
The EGFP-MYO10DF2F3 and EGFP-MYO10DF3 constructs were generated by replacing the wild-type MYO10-FERM domain
(boundaries 1504-2056 in MYO10) with truncated MYO10 FERM domains where the F2-F3 or F3 FERM lobes are deleted using
gene blocks (IDT). The gene blocks were inserted in EGFP-MYO10 using the PvuI and XbaI restriction sites. The final boundaries
compared to full-length MYO10 are 1-1794 for MYO10DF2F3 and 1-1951 for MYO10DF3.
siRNA-mediated gene silencing
The expression of proteins of interest was suppressed using 83 nM siRNA and lipofectamine 3000 (Thermo Fisher Scientific) accord-
ing to the manufacturer’s instructions. All siRNAs used were purchased fromQIAGEN. siMYO10 #7 targets the 30 UTR of the MYO10
mRNA and therefore does not affect the expression of MYO10 constructs.
SDS–PAGE and quantitative western blotting
Purified proteins or protein extracts were separated under denaturing conditions by SDS–PAGE and transferred to nitrocellulose
membranes using Trans-Blot Turbo nitrocellulose transfer pack (Bio-Rad, 1704159). Membranes were blocked for 45 min at room
temperature using 1x StartingBlock buffer (Thermo Fisher Scientific, 37578). After blocking, membranes were incubated overnight
with the appropriate primary antibody (1:1000 in PBS), washed three times in TBST, and probed for 40 min using a fluorophore-con-
jugated secondary antibody diluted 1:5000 in the blocking buffer. Membranes werewashed three times using TBST, over 15min, and
scanned using an Odyssey infrared imaging system (LI-COR Biosciences).
siRNA screen
96-well glass-bottom plates (Cellvis, P96-1.5H-N) were first coated with a solution of poly-D-lysine (10 mg/ml in PBS, Sigma-Aldrich,
A-003-M) at 4Covernight. Plates were thenwashedwith PBS and coatedwith a solution containing 10 mg/ml of bovine fibronectin (in
PBS) also at 4C overnight. Excess fibronectin was washed away with PBS.
U2-OS cells stably expressing MYO10-GFP were silenced for the gene of interest using a panel of siRNAs (QIAGEN flexiplate,
1704159) using Lipofectamine 3000 (Thermo Fisher Scientific, L3000075). 48 h post silencing, cells were trypsinized and plated
on both fibronectin-coated 96-well glass-bottom plates and 96-well plastic-bottom plates in full culture medium. Cells plated in
the plastic-bottom plates were allowed to spread for two hours before being lysed using an RNA extraction buffer. RNAs were
then purified and the silencing efficiency of each siRNA was validated by qPCR analysis.
Cells plated in the glass-bottom plates were allowed to spread for two hours and fixed with a warm solution of 4% paraformalde-
hyde (PFA; Thermo Scientific, 28906). After washing, the samples were incubated with a solution of 1 M glycine (30 min, in PBS) and
then for one hour in a solution containing phalloidin–Atto647N (1/400 in PBS, Thermo Fisher Scientific, 65906) and DAPI (0.5 mg/ml in
PBS, Thermo Fisher Scientific, D1306). The 96-well glass-bottom plates were then imaged using a spinning-disk confocal micro-
scope equippedwith a 40x objective. Images were analyzed using Fiji (Schindelin et al., 2012). Briefly, images were opened and, after
background subtraction and normalization, MYO10 spots were automatically detected using Michael Schmid’s ‘Find maxima’ plu-
gin. As inactive MYO10 is known to accumulate in rab7 vesicles (Plantard et al., 2010), to obtain an accurate number of filopodia-
specific MYO10 spots, intracellular MYO10 spots were excluded from the analysis. Intracellular MYO10 spots were automatically
filtered by masking the cells using the F-actin staining. The remaining spots per field of view were counted.
RNA extraction, cDNA preparation, and Taq-Man qPCR
Total RNA extracted using the NucleoSpin RNA Kit (Macherey-Nagel, 740955.240C) was reverse transcribed into cDNA using the
high-capacity cDNA reverse transcription kit (Applied Biosystems, Thermo Fisher Scientific, 43-688-14) according to the manufac-
turer’s instructions. The TaqMan primer sequences and associated universal probes were generated using ProbeFinder (version
2.53, Roche). The primers themselves were ordered from IDT, and the TaqMan fast advanced master mix (Thermo Fisher Scientific,
4444557) was used to perform the qPCR reactions according to the manufacturer’s instructions. qPCR reactions were analyzed
with the 7900HT fast RT-PCR System (Applied Biosystems), and the results were analyzed using the RQManager Software (Appliede5 Cell Reports 36, 109716, September 14, 2021
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OPEN ACCESSBiosystems). Relative expression was calculated by the 2-DDCT method. GAPDH mRNA levels were used to normalize data between
experiments and conditions.
Generation of filopodia maps
U2-OS cells transiently expressing the constructs of interests were plated on high tolerance glass-bottom dishes (MatTek Corpora-
tion, coverslip #1.7) pre-coated first with Poly-L-lysine (10 mg/ml, 1 h at 37C) and thenwith bovine plasma fibronectin (10 mg/ml, 2 h at
37C). After 2 h, samples were fixed and permeabilized simultaneously using a solution of 4% (wt/vol) PFA and 0.25% (vol/vol) Triton
X-100 for 10 min. Cells were then washed with PBS, quenched using a solution of 1 M glycine for 30 min, and, when appropriate,
incubated with the primary antibody for 1 h (1:100). After three washes, cells were incubated with a secondary antibody for 1 h
(1:100). Samples were then washed three times and incubated with SiR-actin (100 nM in PBS; Cytoskeleton; catalog number:
CY-SC001) at 4C until imaging (minimum length of staining, overnight at 4C; maximum length, one week). Just before imaging,
samples were washed three times in PBS and mounted in Vectashield (Vector Laboratories).
To map the localization of each protein within filopodia, images were first processed in Fiji (Schindelin et al., 2012) and data
analyzed using R as previously described (Jacquemet et al., 2019). Briefly, in Fiji, the brightness and contrast of each imagewas auto-
matically adjusted using, as an upper maximum, the brightest cellular structure labeled in the field of view. In Fiji, line intensity profiles
(1-pixel width) were manually drawn from filopodium tip to base (defined by the intersection of the filopodium and the lamellipodium).
To avoid any bias in the analysis, the intensity profile lines were drawn from a merged image. All visible filopodia in each image were
analyzed and exported for further analysis (export was performed using the ‘‘Multi Plot’’ function). For each staining, line intensity
profiles were then compiled and analyzed in R. To homogenize filopodia length; each line intensity profile was binned into 40 bins
(using the median value of pixels in each bin and the R function ‘‘tapply’’). Using the line intensity profiles, the percentage of filopodia
positive for active b1 at their tip was quantified. A positive identification was defined as requiring at least an average value of 5000
(values between 0-65535) within the bins defining the filopodium tip (identified using MYO10 staining). The map of each protein of
interest was created by averaging hundreds of binned intensity profiles. The length of each filopodium analyzed was directly ex-
tracted from the line intensity profiles.
The preferential recruitment of active and inactive b1 integrin to filopodia tips or shafts was assessed by calculating an enrichment
ratio where the averaged intensity of the b1 integrin species at the filopodium tip (bin 1-6) was divided by the averaged intensity at the
filopodium shaft (bin 7-40). This enrichment ratio was calculated for each filopodium analyzed and the results were displayed as Tu-
key boxplots.
Quantification of filopodia numbers and dynamics
For the filopodia formation assays, cells were plated on fibronectin-coated glass-bottom dishes (MatTek Corporation) for 2 h. Sam-
ples were fixed for 10 min using a solution of 4% PFA, then permeabilized using a solution of 0.25% (vol/vol) Triton X-100 for 3 min.
Cells were then washed with PBS and quenched using a solution of 1 M glycine for 30 min. Samples were then washed three times in
PBS and stored in PBS containing SiR-actin (100 nM; Cytoskeleton; catalog number: CY-SC001) at 4C until imaging. Just before
imaging, samples were washed three times in PBS. Images were acquired using a spinning-disk confocal microscope (100x objec-
tive). The number of filopodia per cell was manually scored using Fiji (Schindelin et al., 2012).
To study filopodia stability, U2-OS cells expressing MYO10-GFP were plated for at least 2 h on fibronectin before the start of live
imaging (pictures taken every 5 s at 37C, on an Airyscan microscope, using a 40x objective). All live-cell imaging experiments were
performed in normal growth media, supplemented with 50 mM HEPES, at 37C and in the presence of 5% CO2. Filopodia lifetimes
were then measured by identifying and tracking all MYO10 spots using the Fiji plugin TrackMate (Tinevez et al., 2017). In TrackMate,
the LoGdetector (estimated bob diameter = 0.8mm; threshold = 20; subpixel localization enabled) and the simple LAP tracker (linking
max distance = 1 mm; gap-closing max distance = 1 mm; gap-closing max frame gap = 0) were used.
Light microscopy setup
The spinning-disk confocal microscope (spinning-disk confocal) used was a Marianas spinning-disk imaging system with a Yoko-
gawa CSU-W1 scanning unit on an inverted Zeiss Axio Observer Z1 microscope controlled by SlideBook 6 (Intelligent Imaging In-
novations, Inc.). Images were acquired using either an Orca Flash 4 sCMOS camera (chip size 2,0483 2,048; Hamamatsu Photonics)
or an Evolve 512 EMCCD camera (chip size 5123 512; Photometrics). Objectives used were a 40x water (NA 1.1, LD C-Apochromat,
Zeiss), a 63 3 oil (NA 1.4, Plan-Apochromat, M27 with DIC III Prism, Zeiss) and a 100x oil (NA 1.4 oil, Plan-Apochromat, M27)
objective.
The structured illumination microscope (SIM) used was DeltaVision OMX v4 (GE Healthcare Life Sciences) fitted with a 60x Plan-
Apochromat objective lens, 1.42 NA (immersion oil RI of 1.516) used in SIM illumination mode (five phases x three rotations). Emitted
light was collected on a front-illuminated pco.edge sCMOS (pixel size 6.5 mm, readout speed 95 MHz; PCO AG) controlled by
SoftWorx.
The confocal microscope used was a laser scanning confocal microscope LSM880 (Zeiss) equipped with an Airyscan detector
(Carl Zeiss) and a 40x oil (NA 1.4) objective. Themicroscope was controlled using Zen Black (2.3), and the Airyscan was used in stan-
dard super-resolution mode.Cell Reports 36, 109716, September 14, 2021 e6
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CHO cells detached using Hyclone HyQTase (Thermo Fisher Scientific, SV300.30.01), washed with Tyrode’s Buffer (10 mM HEPES-
NaOH, pH 7.5, 137 mM NaCl, 2.68 mM KCl, 0.42 mM NaH2PO4, 1.7 mM MgCl2, 11.9 mM NaHCO3, 5 mM glucose, and 0.1% BSA)
and pretreated for 10 min with or without 5 mM EDTA in serum-free alpha-MEM media. Cells were then incubated for 40 min with
Alexa Fluor 647 labeled fibronectin fragment (FN 7-10). After washing away the unbound fibronectin using Tyrode’s buffer, cells
were fixed with 4% PFA (in PBS) for 10 min at room temperature. Part of the HyQTase treated cells were also fixed with 4% PFA
(in PBS) and stainedwith an anti-hamster anti-ɑ5 integrin antibody to detect total ITGA5 levels in cells (2 h at 4C, 1:10 in PBS, antibody
PB1, Developmental studies hybridoma bank) and with an Alexa Fluor 647-conjugated secondary antibody (45 min at RT, 1:200 in
PBS, Thermo Fisher Scientific, A-21235). Fluorescence intensity was recorded using FACS (BD LSRFortessa). Data were gated and
analyzed using the Flowing Software (https://bioscience.fi/services/cell-imaging/flowing-software/). The integrin activity index (IA)
was calculated for each condition as a ratio AI = (FFEDTA)/(FPB1), where F = FN7-10 signal, FEDTA = FN7-10 signal in EDTA treated
cells and FPB1 = ɑ5 integrin signal.
MDA-MB-231 and U2-OS cells detached using Hyclone HyQTase (Thermo Fisher Scientific, SV300.30.01) were fixed with 4%PFA
(in PBS) for 10 min and stained for active (antibody 9EG7) and total b1 integrin (antibody P5D2) overnight at 4C. Cells were then
stained with the appropriate Alexa Fluor 647-conjugated secondary antibody (45 min at RT, 1:200, Thermo Fisher Scientific) and
the fluorescence was recorded using FACS. Data were gated and analyzed using the Flowing Software (https://bioscience.fi/
services/cell-imaging/flowing-software/) and the integrin activity (IA) was calculated as indicated below where F9EG7 and FP5D2
are the signals intensities of the 9EG7 and P5D2 stainings, respectively. F2nd Ab corresponds to the signal intensity recorded
when the cells are stained with only the secondary antibody.
IA = ðF9EG7  F2nd AbÞ = ðFP5D2  F2nd AbÞCell spreading assay
The xCELLigence RTCA instrument (Roche) was used to measure cell adhesion on fibronectin in real-time (Hamidi et al., 2017). The
RTCA instrument uses gold-bottom electrode plates to measure the impedance between two electrodes. This is expressed as an
arbitrary cell index value. The xCELLigence 96-well plates (Acea Biosciences, E-Plate VIEW 96 PET, 00300600900) were coated
with a solution of 20 mg/ml of poly-D-lysine (in PBS) for 1 h at 37C, washed with PBS, and coated with a solution of 10 mg/ml fibro-
nectin (in PBS) for 1 h at 37C. Plates were then blocked using a solution of 1%BSA (in PBS) for 1 h in RT. After 2 PBSwashes, 15000
cells were seeded into each well in a serum-free culture medium. The cell index was recorded over time.
Recombinant protein expression and purification
The E. coli BL-21(DE3) strain was transformed with IPTG inducible, His-tagged expression constructs, and the transformed bacteria
were grown at 37C in LB media supplemented with ampicillin (1 mg/ml) until OD600 was 0.6-0.8. Protein expression was then
induced using IPTG (0.5 mM), and the temperature was lowered to 25C. Cells were harvested after 5 h by centrifugation (20 min
at 6000 g). Bacteria were then resuspended in a resuspension buffer (1x TBS, cOmplete protease inhibitor tablet (Roche, cat. no.
5056489001), 1x AEBSF inhibitor, 1x PMSF, RNase 0.05 mg/ml, DNase 0.05 mg/ml). To lyse the bacteria, a small spoonful of lyso-
zyme and 1x BugBuster (Merck Millipore, cat. no. 70584-4) were added, and the suspension was agitated for 30 min at 4C. Cell
debris was pelleted using a JA25.5 rotor at 20000 rpm for 1 h. His-tagged proteins were batch purified from the supernatant using
a Protino Ni-TED 2000 column (Macherey Nagel, cat. no. 745120.25) according to the manufacturer’s instructions. Proteins were
eluted using the elution buffer provided with the kit supplemented with 1mMAEBSF. For each purified protein, several 1 mL fractions
were collected, ran on a 4%–20% protein gel (Bio-Rad Mini-PROTEAN TGX, #4561093), stained with InstantBlue (Expedeon,
ISB1L), and the fractions abundant in tagged protein were combined. Imidazole was removed in a buffer exchange overnight at
4C and 1 mM AEBSF was added to the imidazole-free protein. Proteins were stored at 4C for up to one week.
Whole-mount immuno-SEM
U2-OS cells expressing MYO10-GFP were plated for 2 h on fibronectin-coated coverslips and fixed with a solution of 4% PFA (in
0.1 M HEPES, pH 7.3) for 30 min. After washing and quenching with 50 mM NH4Cl (in 0.1 M HEPES), non-specific binding was
blocked with a buffer containing 2% BSA (in 0.1 M HEPES). Samples were then labeled using the appropriate primary antibody
(1:10 in 0.1 M HEPES) for 30 min, washed, and labeled with a gold conjugated secondary antibody (1:50 in 0.1 M HEPES, 30 nm
gold particles, BBI solutions, EM.GAF30) for 30 min. After immunolabeling, the samples were washed, and post-fixed with a solution
of 2.5% glutaraldehyde and 1% buffered osmium tetroxide prior to dehydration and drying using hexamethyldisilazane. The dried
samples were mounted on SEM stubs and sputter-coated with carbon. The micrographs were acquired with FEI Quanta FEG 250
microscope with SE and vC detectors (FEI Comp.) using an acceleration voltage of 5.00 kV and a working distance ranging from
7.7 to 10.9 mm.
To compare the distribution of active and inactive integrin from EM images, we manually measured the distance between each
detected gold particle and the filopodium tip using Fiji. Results were then plotted as a probability density function where the area
under the curve represents 100% probability. A bootstrap version of the univariate Kolmogorov-Smirnov test was then used to
assess statistical significance (using Rstudio). Importantly, filopodia length was not normalized in these analyses.e7 Cell Reports 36, 109716, September 14, 2021
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For each pulldown, 20 mL of streptavidin Dynabeads (MyOne Streptavidin C1, Invitrogen, 65001) were incubated, for 30 min, on ice,
with the appropriate biotinylated integrin tail peptides (50 ug per sample) (LifeTein). U2-OS cells were washed twice with cold PBS
and lysed on ice with a buffer containing 40 mM HEPES, 75 mM NaCl, 2 mM EDTA, 1% NP-40, a cOmplete protease inhibitor tablet
(Roche, 5056489001) and a phosphatase-inhibitor tablet (Roche, 04906837001). Samples were cleared by centrifugation (13,000 g,
10 min) and incubated with the streptavidin Dynabeads for 2 h at 4C. Beads were washed three times with a washing buffer (50 mM
Tris-HCl pH 7.5, 150mMNaCl, 1% (v/v) NP-40), and proteins bound to the beadswere eluted using SDS sample buffer and heated for
5-10 min at 90C. Results were analyzed using western blots. Integrin peptides used were wild-type b1-integrin tail (KLLMIIHDRR
EFAKFEKEKMNAKWDTGENPIYKSAVTTVVNPKYEGK), the b1-integrin tail where the NPXY motif is deleted (KLLMIIHDRREFAKFE-
KEKMNAKWDTGEN), the conserved region of the a2-integrin tail (WKLGFFKRKYEKM), the conserved region of a2-integrin tail pep-
tide where the GFFKR motif is mutated (GAAKR mutant, WKLGAAKRKYEKM) and the wild-type a5-integrin tail (KLGFFKRS
LPYGTAMEKAQLKPPATSDA).
Microscale thermophoresis
Recombinant His-tagged proteins were labeled using theMonolith His-Tag Labeling Kit RED-tris-NTA (NanoTemper,MO-L008). In all
experiments, the labeled His-tagged recombinant proteins were used at a concentration of 20 nMwhile the integrin tail peptides were
used at increasing concentration. Kd values were calculated using the equation provided below (Equation 1), where Kd is the disso-
ciation constant, [A] the concentration of the free fluorescent molecule, [L] the concentration of the free ligand, [AL] the concentration
of the AL-complex. [A0] is the known concentration of the fluorescent molecule and [L0] is the known concentration of added ligand.
This leads to a quadratic fitting function for [AL]:
½AL = 1=2  ðð½A0 + ½L0 + KdÞ ðð½A0 + ½L0 + KdÞ2 4  ½A0  ½L0Þ1 = 2Þ Eq.1
Alternatively, binding was also expressed as a change in MST signal (normalized fluorescence DFnorm). This is defined as a ratio:
DFnorm = F1=F0 Eq.2
Where F0 is the fluorescence prior and F1 after IR laser activation.
All binding data were analyzed using MO.Control and MO.Affinity software (NanoTemper).
QUANTIFICATION AND STATISTICAL ANALYSIS
Randomization tests were performed using the online tool PlotsOfDifferences (https://huygens.science.uva.nl/PlotsOfDifferences/)
(Goedhart, 2019). Dot plots were generated using PlotsOfData (Postma and Goedhart, 2019). SuperPlots were generated using
SuperPlotsofData (Lord et al., 2020; Goedhart, 2021). Bar plots with visualized data points, time-series data, and density plots
were generated using R (https://www.r-project.org/), Rstudio (Integrated Development for R. RStudio, Inc., Boston, MA. https://
www.rstudio.com/) and ggplot2 (Wickham, 2016). The univariate Kolmogorov-Smirnov test was performed using Rstudio. Other sta-
tistical analyses were performed using Google sheets except for the one-sample t test which was performed using an online calcu-
lator (https://www.socscistatistics.com/tests/tsinglesample/default.aspx).Cell Reports 36, 109716, September 14, 2021 e8
